Intervention Review

Pregabalin add-on for drug-resistant partial epilepsy

  1. Jennifer Pulman1,*,
  2. Karla Hemming2,
  3. Anthony G Marson1

Editorial Group: Cochrane Epilepsy Group

Published Online: 12 MAR 2014

Assessed as up-to-date: 3 MAR 2014

DOI: 10.1002/14651858.CD005612.pub3


How to Cite

Pulman J, Hemming K, Marson AG. Pregabalin add-on for drug-resistant partial epilepsy. Cochrane Database of Systematic Reviews 2014, Issue 3. Art. No.: CD005612. DOI: 10.1002/14651858.CD005612.pub3.

Author Information

  1. 1

    Institute of Translational Medicine, University of Liverpool, Department of Molecular and Clinical Pharmacology, Liverpool, Merseyside, UK

  2. 2

    University of Birmingham, Public Health, Epidemiology and Biostatistics, Birmingham, UK

*Jennifer Pulman, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Clinical Sciences Centre for Research and Education, Lower Lane, Fazakerley, Liverpool, Merseyside, L9 7LJ, UK. jennifer.pulman@liv.ac.uk.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 12 MAR 2014

SEARCH

Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

Login via OpenAthens

or

Search for your institution's name below to login via Shibboleth.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

Patient Access

Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.